List view / Grid view
19 March 2014 | By Daiichi Sankyo
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
17 March 2014 | By Amgen
Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
17 March 2014 | By Bristol-Myers Squibb
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies...
13 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reduction in the frequency of exacerbations...
12 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
12 March 2014 | By Sanofi
Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules...
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
6 March 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound...
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
5 March 2014 | By Merck
MSD announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237)...
5 March 2014 | By Biogen Idec
Eisai Co., Ltd. and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease, E2609 and BAN2401...
3 March 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...
3 March 2014 | By Roche
Roche announced that an independent data monitoring committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy...
27 February 2014 | By Freddy White, Drug Target Review
Michael Bjerke, Promega's Global Product Manager, Detection, speaks to Freddy White at SLAS 2014.
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
